Agios Pharmaceuticals (AGIO) Current Assets (2012 - 2026)

Agios Pharmaceuticals' Current Assets history runs 15 years deep, the most recent figure standing at $834.8 million for Q1 2026.

• Quarterly Current Assets fell 13.81% year-over-year to $834.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $834.8 million (down 13.81% YoY) and the FY2025 annual result came in at $942.1 million, down 2.44% from the prior year.
• Current Assets was $834.8 million for Q1 2026 at Agios Pharmaceuticals, down from $942.1 million in the prior quarter.
• Across five years, Current Assets topped out at $1.1 billion in Q3 2024 and bottomed at $632.1 million in Q2 2024.
• A 5-year average of $863.7 million and a median of $834.8 million in 2026 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets slumped 58.59% — and 2025, when it soared 61.28%.
• Agios Pharmaceuticals' Current Assets stood at $832.8 million in 2022, then climbed by 0.13% to $833.8 million in 2023, then increased by 15.8% to $965.6 million in 2024, then retreated by 2.44% to $942.1 million in 2025, then retreated by 11.38% to $834.8 million in 2026.
• Business Quant data shows AGIO's Current Assets at $834.8 million in Q1 2026, $942.1 million in Q4 2025, and $1.0 billion in Q3 2025.